Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
12-13-2021

Peroxisomal β-oxidation
-oxidation acts as a sensor for intracellular fatty
acids and regulates lipolysis
Lianggong Ding
Wenfei Sun
Miroslav Balaz
Anyuan He
Manuel Klug

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Authors
Lianggong Ding, Wenfei Sun, Miroslav Balaz, Anyuan He, Manuel Klug, Stefan Wieland, Robert Caiazzo,
Violeta Raverdy, Francois Pattou, Philippe Lefebvre, Irfan J Lodhi, Bart Staels, Markus Heim, and Christian
Wolfrum

Articles
https://doi.org/10.1038/s42255-021-00489-2

Peroxisomal β-oxidation acts as a sensor for
intracellular fatty acids and regulates lipolysis
Lianggong Ding1, Wenfei Sun1, Miroslav Balaz1,2,3, Anyuan He4,5, Manuel Klug1, Stefan Wieland6,
Robert Caiazzo7, Violeta Raverdy7, Francois Pattou7, Philippe Lefebvre8, Irfan J. Lodhi4, Bart Staels8,
Markus Heim6,9 and Christian Wolfrum 1 ✉
To liberate fatty acids (FAs) from intracellular stores, lipolysis is regulated by the activity of the lipases adipose triglyceride
lipase (ATGL), hormone-sensitive lipase and monoacylglycerol lipase. Excessive FA release as a result of uncontrolled lipolysis
results in lipotoxicity, which can in turn promote the progression of metabolic disorders. However, whether cells can directly
sense FAs to maintain cellular lipid homeostasis is unknown. Here we report a sensing mechanism for cellular FAs based on
peroxisomal degradation of FAs and coupled with reactive oxygen species (ROS) production, which in turn regulates FA release
by modulating lipolysis. Changes in ROS levels are sensed by PEX2, which modulates ATGL levels through post-translational
ubiquitination. We demonstrate the importance of this pathway for non-alcoholic fatty liver disease progression using genetic
and pharmacological approaches to alter ROS levels in vivo, which can be utilized to increase hepatic ATGL levels and ameliorate hepatic steatosis. The discovery of this peroxisomal β-oxidation-mediated feedback mechanism, which is conserved in
multiple organs, couples the functions of peroxisomes and lipid droplets and might serve as a new way to manipulate lipolysis
to treat metabolic disorders.

P

eroxisomes are organelles, which are present in virtually
all eukaryotic cells and play an important role in numerous
processes, linked to lipid metabolism1. While medium- and
long-chain FAs are mainly oxidized in mitochondria and to a lesser
degree in peroxisomes2,3, very-long-chain FAs (VLCFAs) are almost
exclusively metabolized by β-oxidation in peroxisomes4, exemplified by increased plasma VLCFA levels5 in various peroxisome biogenesis disorders. The rate-limiting step in peroxisomal β-oxidation
is dependent on acyl-CoA oxidase 1 (ACOX1), a peroxisomal
matrix protein, which catalyzes desaturation of acyl-CoAs to
2-trans-enoyl-CoAs, resulting in generation of hydrogen peroxide
(H2O2), which accounts for up to 35% of the total H2O2 production
in mammalian tissues6. ACOX1 loss of function leads to pseudoneonatal adrenoleukodystrophy, increased plasma VLCFA levels and
glial degeneration7. Conversely, ACOX1 gain-of-function mutations
result in a progressive glial degeneration, due to enhanced oxidative
stress caused by excessive H2O2 production, which can be pharmacologically attenuated by treatment with the antioxidant N-acetyl
cysteine amide (NACA)8. To efficiently counteract the oxidative
stress caused by elevated peroxisomal β-oxidation, peroxisomes
import catalase (CAT) into the matrix, which can convert H2O2 into
H2O and O2 (ref. 9).
To import matrix proteins into peroxisomes, a coordinated function of different peroxins (PEXs) is required. The cytosolic receptors
PEX5 and PEX7 recognize and interact with peroxisome-targeting
sequence-1 (PTS1) and -2 (PTS2) containing cargo proteins,
complemented by docking to the peroxisomal membrane through

PEX13 and PEX14 (ref. 5). The peroxisomal membrane proteins PEX2/10/12, three RING (Really Interesting New Gene)
finger E3 ligases, ubiquitinate PEX5 to initiate PEX5 recycling
into cytosol or for further degradation5. In addition to PEX5
ubiquitination, PEX2 also plays an important role in pexophagy
regulation and only the levels of PEX2 among the PEX2–PEX10–
PEX12 protein complex are strictly controlled at normal state via
an unknown mechanism10.
Lipid droplets (LDs) are storage organelles for lipid deposition
that are mainly composed of neutral lipids such as triacylglycerols
(TAGs) and cholesteryl esters (CEs)11. In times of energy demand,
LDs are depleted by TAG hydrolysis to liberate FA by either lipolysis or lipophagy, which are intricately regulated by insulin and catecholamines12. Lipolysis is mainly driven by the action of ATGL,
hormone-sensitive lipase (HSL) and monoacylglycerol lipase
(MGL), which convert TAGs in a stepwise fashion into glycerol and
FAs12–14. The first rate-limiting enzyme ATGL mainly localizes in
the adipocyte cytosol in the basal state and is recruited to the LD
surface upon hormonal stimulation15. However, ATGL is normally
tethered on the LD surface through a hydrophobic domain (HD) in
non-adipocyte cells13,15.
It is well documented that peroxisomes and LDs are in physical contact within cells16. Apart from a recent report demonstrating
that peroxisome–LD contacts are essential for ATGL redistribution
to the LD surface upon hormone stimulation in adipocytes17, the
molecular basis for physical interaction and functional interconnectivity of the two organelles remains largely unexplored. Here we
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Fig. 1 | PEX2 downregulation increases iBA lipolysis and ATGL protein levels in various cell types via reduced poly-ubiquitination. a,b, Levels of glycerol
and NEFAs in starvation medium released by iBAs in basal state (n = 4; F = 6.491 (a) and 6.884 (b)). c, IB of HSLSer660ph, HSL, ATGL, CGI-58, PLIN1 and
γ-tubulin in iBAs 72 h after Pex2 knockdown (n = 6 in Pex2 and 12 in Nc siRNA, F = 27.6). d, Representative immunofluorescence (IF) result of ATGL in
iBAs 72 h after Pex2 knockdown. ATGL in red, LDs in green and nuclei in blue. Scale bar, 20 μm. Experiments were repeated four times. e, IB of ATGL and
γ-tubulin in HepG2 cells 48 h after PEX2 knockdown (n = 6 in Pex2 and 10 in Nc siRNA, F = 23.94). f,g, IB of endogenous ATGL or ectopically expressed
ATGL–FLAG and γ-tubulin in HEK293T cells 48 h after PEX2 knockdown (n = 6 in Pex2 and 12 in Nc siRNA; F = 17.66 (f) and 20.9 (g)). Results are shown as
the mean ± s.e.m. and analysed using ANOVA with Dunnett correction for multiple comparisons between control and other groups. Statistical differences
are indicated by exact P values.

show that peroxisomal β-oxidation functions as a sensor of intracellular FAs and regulates lipolysis via ATGL ubiquitination.

Results

PEX2/10/12 modulate lipolysis by regulating ATGL protein. Peroxisomal β-oxidation accounts for a substantial part of
the overall cellular FA degradation within a cell3 and the physical interaction between LDs and peroxisomes has been shown
to facilitate LD-derived FA trafficking into peroxisomes16. Based
on this interaction, we hypothesized that a functional crosstalk
exists between both organelles to regulate the degradation of FAs
to maintain lipid homeostasis. To test this hypothesis, we utilized murine immortalized brown adipocytes (iBAs) and HepG2
cells, because of their abundant content of both peroxisomes and
LDs18,19. First, we determined peroxisome and LD distribution in
Nature Metabolism | VOL 3 | December 2021 | 1648–1661 | www.nature.com/natmetab

both cell types and we observed, as reported previously, close contacts between the two organelles16,20 (Extended Data Fig. 1a,b). To
investigate a possible functional crosstalk between both organelles,
we studied the effect of PEX proteins, which are key mediators of
peroxisomal function, on lipolysis by utilizing a small-scale screen
in iBAs (Extended Data Fig. 1c). We observed that both Pex2/12
depletion increased glycerol levels and FA release (Fig. 1a,b), suggesting an elevated lipolytic activity. A validation using different
single short-interfering RNAs (siRNAs) confirmed that depletion
of Pex2/10/12 enhanced basal lipolysis, whereas Pex2/12 knockdown enhanced stimulated lipolysis (Extended Data Fig. 1d,e).
Peroxisome proliferator-activated receptor-γ 2 (Pparg2), adiponectin (Adipoq) messenger RNA (Extended Data Fig. 1f–h) as well
as the overall rate of differentiation did not change in response to
the depletion of Pex2/10/12 (Extended Data Fig. 1i,j), suggesting
1649
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Fig. 2 | PEX2 modulates ATGL protein levels via K48-linkage poly-ubiquitination. a, Co-IP conducted in HEK293T whole cell extract (WCE) via
FLAG antibody 48 h after expressing PEX2–FLAG. Co-IP was analysed by IB using the indicated antibodies. Experiments were repeated three times.
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were repeated three times. c,d, IB of ectopically expressed ATGL3KR–EGFP and ATGLΔHD–EGFP in HEK293T cells 48 h after PEX2 siRNA transfection
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that the observed effect is not due to alterations in the adipogenic
process. Similarly, we observed a change in peroxisomal mass after
PEX2 ablation, but not after PEX10/12 depletion (Extended Data
Fig. 1k–m), which suggests that changes in peroxisomal mass are
not required to affect the lipolytic process. To identify the mechanism by which Pex2/10/12 depletion could induce lipolysis, we
analysed several key regulators of lipolysis (Fig. 1c). Among the
tested candidates only ATGL protein, a lipase reported to regulate lipolysis at both basal and activated state21, was significantly
1650

increased upon Pex2/10/12 ablation (Fig. 1c and Extended Data
Fig. 2a,b), which was further confirmed by immunostaining
(Fig. 1d and Extended Data Fig. 2c). In accordance with this observation, ATGL activity levels were increased upon Pex2 knockdown
(Extended Data Fig. 2d). Notably, Atgl transcript levels remained
unchanged (Extended Data Fig. 2e), suggesting that ATGL protein
levels are modulated in a post-transcriptional manner. Moreover,
this regulatory process is limited to PEX2/10/12, as other peroxins
such as PEX5 and PEX19 did not affect ATGL levels (Extended
Nature Metabolism | VOL 3 | December 2021 | 1648–1661 | www.nature.com/natmetab
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Fig. 3 | Peroxisomal β-oxidation-derived ROS regulate PEX2 protein levels. a,b, HepG2 cells with PEX2–FLAG expression were transfected with CAT or
ACOX1 siRNAs. After 48 h, IP and IB were conducted using the indicated antibodies (n = 4 in CAT or ACOX1 and 8 in Nc siRNA, F = 19.79 (a) and 29.46 (b)).
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Data Fig. 2f,k). This functional crosstalk between peroxisomes
and lipolysis from LDs was confirmed in both HepG2 and
HEK293T cells (Fig. 1e–g and Extended Data Fig. 2g–p), suggesting that it constitutes a conserved regulatory mechanism.
Nature Metabolism | VOL 3 | December 2021 | 1648–1661 | www.nature.com/natmetab

PEX2 regulates ATGL turnover via poly-ubiquitination. To
uncover the mechanism by which peroxisomal function is linked to
the control of lipolysis through modulation of ATGL protein levels,
we first analysed whether the effect was due to a direct interaction of
1651
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PEX2 and ATGL. To address this point, we expressed FLAG-tagged
human PEX2 (PEX2–FLAG) and induced LD formation by addition of oleic acid, followed by immunoprecipitation (IP) of PEX2.
Ectopically expressed PEX2 protein levels were quite low even after
transient transfection (Fig. 2a and Extended Data Fig. 3a), possibly
due to a tight regulation by proteasomal degradation10. In spite of
the low PEX2 levels, we were able to identify endogenous ATGL and
ectopically expressed ATGL–FLAG, but not other LD-associated
proteins such as CGI-58 and adipose differentiation-related protein (ADRP), as interaction partners of PEX2 (Fig. 2a and Extended
Data Fig. 3a,b). The direct interaction between ATGL and PEX2 was
further confirmed using a proximity ligation assay (PLA) (Extended
Data Fig. 3c).
As ATGL mostly localizes to the LD surface in non-adipocyte
cells22, we next investigated whether regulation takes place at the
peroxisome/LD contact sites. Therefore, we ablated the ΔHD of
human ATGL to express an ATGLΔHD–enhanced green fluorescent protein (EGFP) fusion protein (Extended Data Fig. 3d)15
that does not target the LD surface. Furthermore, we generated a
mutated ATGL in which all three lysine residues in the HD were
changed to arginine (ATGL3KR–EGFP) to assess whether the lysine
residues in the HD are dispensable for ATGL regulation by PEX2
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(Extended Data Fig. 3d). As expected, both wild-type ATGL and
ATGL3KR mainly colocalized with LDs, whereas ATGLΔHD did
not (Fig. 2b). Furthermore, ATGL3KR levels were elevated upon
PEX2 ablation, whereas levels of ATGLΔHD remained unaltered
(Fig. 2c,d). These data demonstrate that LD localization of ATGL is
required for its post-translational regulation by PEX2.
To uncover how changes in PEX2 levels led to an increase
in ATGL levels and lipolysis, we focused on ubiquitination and
proteasome-targeted degradation. We observed that when ATGL–
FLAG was coexpressed with haemagglutinin (HA)-tagged ubiquitin
(Ub), while PEX2 expression was ablated, ATGL poly-ubiquitination
was reduced both in the presence or absence of MG132, suggesting that PEX2 itself is responsible for poly-ubiquitinating ATGL
to target it for proteasomal degradation (Fig. 2e). Furthermore, we
showed that PEX2 regulated ATGL by K48- but not by K63-linked
poly-ubiquitination (Fig. 2f,g).
Based on our findings that PEX2 can induce K48-linked
poly-ubiquitination of ATGL, we next investigated which lysine residue in ATGL is targeted by PEX2. Both human and murine ATGL
contain 15 lysine residues, of which 12 are conserved (Extended
Data Fig. 3d). We first mutated all lysine residues of human ATGL
into arginine to generate a lysine-null mutant (K0). Subsequently,
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we mutated each arginine into lysine in the K0 mutant to obtain
15 site-specific lysine-only mutants. General proteasomal degradation of ATGL was dependent on multiple lysine residues (Extended
Data Fig. 4a); however, only the K92-only mutant was responsive to
PEX2 modulation (Fig. 2h and Extended Data Fig. 4b,c). To obtain
1654

a spatial resolution, we measured ATGL ubiquitination levels in the
LD and cytosol fractions from iBAs in both a basal and stimulated
state. In accordance with our previous results, we showed that PEX2
ubiquitinates ATGL in both LD and cytosol fractions to regulate
its levels and lipolytic activity (Extended Data Fig. 4d–g). Instead,
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we observed no changes in ADRP ubiquitination levels after
PEX2 depletion, suggesting specific regulation of ATGL by PEX2
(Extended Data Fig. 4h).
Taken together, our data demonstrate that PEX2 specifically
poly-ubiquitinates lipolytic protein ATGL at the K92 site when
ATGL distributes on the LD surface for proteasome-targeted degradation in different cell types.
PEX2 acts as a ROS sensor in peroxisomes. PEX2 protein levels
are tightly controlled and kept at a low level via a so-far-unknown
mechanism10 (Fig. 2a and Extended Data Fig. 3a). Considering the
role of peroxisomal ROS as a rheostat for peroxisomal homeostasis23, we hypothesized that ROS signalling might be involved
in modulating PEX2 levels, possibly by stabilization of the latter.
Therefore, we manipulated peroxisomal ROS levels by knocking
down the peroxisomal matrix proteins CAT and ACOX1. To measure peroxisomal ROS levels, we constructed a HyPer3 protein24,
with a PTS1 sequence (HyPer3-PTS1) for peroxisomal matrix targeting, which functions as a peroxisomal H2O2 sensor (Extended
Data Fig. 5a). Using this system, we showed that ablation of CAT
expression led to elevated peroxisomal ROS and PEX2 levels (Fig. 3a
and Extended Data Fig. 5b), whereas ACOX1 ablation reduced
peroxisomal ROS and PEX2 levels (Fig. 3b and Extended Data
Fig. 5b,c). To validate this association, we used H2O2 and the antioxidant N-acetyl-l-cysteine (NAC), which reportedly modulate global
ROS levels25 and also affect peroxisomal ROS levels (Extended Data
Fig. 5d). In line with our genetic data, we observed that H2O2 elevated PEX2 but not PEX10 and PEX12 levels (Fig. 3c and Extended
Data Fig. 5e,f), whereas PEX2 protein levels were significantly
reduced upon NAC treatment (Fig. 3d). These findings were confirmed in other cell types (Fig. 3e–i and Extended Data Fig. 5g–k),
suggesting that modulation of PEX2 levels by peroxisomal ROS is a
general regulatory concept. Although PEX2 is involved in the regulation of pexophagy, PEX2 upregulation, induced by peroxisomal
ROS, did not result in a loss of peroxisome mass in iBAs (Extended
Data Fig. 5l,m). Furthermore, we observed that specific targeting
of peroxisomal β-oxidation by the addition of VLCFAs, which are
specific substrates of this process, similarly increased peroxisomal
ROS and PEX2 levels (Fig. 3j and Extended Data Fig. 5j). In addition,
we showed in a chase experiment that PEX2 turnover was reduced
in the presence of H2O2 (Extended Data Fig. 5n), suggesting that its
stability is influenced by peroxisomal ROS levels. Taken together,
these data demonstrate that PEX2 protein levels are modulated
by ROS levels within the peroxisomes, which could provide a link
between peroxisomal β-oxidation and ATGL-mediated lipolysis.
PEX2 stabilization promoted by ROS-sensitive disulfide bonds.
Disulfide bond formation is a basic mechanism to promote stabilization of various proteins. Moreover, formation of disulfide bonds
can be directly regulated by ROS26,27. Hence, we hypothesized that

Articles
ROS might promote PEX2 stability by regulating disulfide bond
formation. We observed that PEX2 displayed an oligomerization
pattern in the non-reducing state and alterations in retention time,
which was abolished in the reducing state (Fig. 4a), demonstrating
that PEX2 can form both intramolecular and intermolecular disulfide bonds in different cell lines (Fig. 4b and Extended Data Fig. 6a).
When we analysed the oligomerization pattern upon H2O2 treatment, we observed that all forms of PEX2 increased (Fig. 4c,d and
Extended Data Fig. 6b), suggesting that both intramolecular and
intermolecular disulfide bond formation contributes to increased
PEX2 stability. Human PEX2 contains 14 cysteines and 12 of them
are conserved between human and murine PEX2 (Fig. 4e). By
generating individual cysteine mutants, we showed that no single
cysteine to glycine substitution could comprehensively disrupt the
oligomerization pattern (Extended Data Fig. 6c). More notably, all
mutants, albeit different in their expression levels, were stabilized
by the addition of H2O2 (Extended Data Fig. 6d), suggesting that
PEX2 disulfide bond formation and stabilization in response to
ROS is dependent on multiple bonds. When we mutated all seven
cysteines outside the RING domain into glycine (PEX2C1-7G), we
observed substantially reduced levels of oligomerization, whereas
the PEX2C8-14G mutant (cysteines of the RING domain) exhibited a normal oligomerization pattern (Fig. 4f). In accordance, we
observed that PEX2C1-7G and PEX2C1-14G lost their responsiveness to changes in ROS levels, whereas the PEX2C8-14G protein
could still be stabilized (Fig. 4g–i). In addition, we showed that cysteines outside and inside the RING domain are required for PEX2
ligase activity as ATGL upregulation induced by endogenous PEX2
depletion could not be rescued by either ectopically overexpression
of PEX2C1-7G and PEXC8-14G (Extended Data Fig. 6e,f). Last, we
analysed PEX2 poly-ubiquitination levels, which were reduced upon
H2O2 treatment in PEX2 but not in PEX2C1-7G (Extended Data
Fig. 6g). These data suggest that oligomerized PEX2 is less prone
to ubiquitination or more resistant to poly-ubiquitination-mediated
degradation. As COP1, an E3 ligase, has been reported to regulate
ATGL in a certain cell types28, we analysed whether this ligase could
regulate ATGL protein levels and function as a ROS sensor similar
to PEX2. We observed neither increased ATGL levels upon COP1
depletion nor elevated COP1 levels in response to H2O2 exposure in
iBAs, which suggests that COP1 is not required for ROS-mediated
regulation of ATGL (Extended Data Fig. 6h,i). Collectively, these
data demonstrate that PEX2 forms intramolecular and intermolecular disulfide bonds, which control its stability in response to alterations in ROS levels.
Peroxisome-derived ROS regulate ATGL and lipolysis levels.
Based on our data, we hypothesized that peroxisomal β-oxidation
itself through ROS production and stabilization of PEX2 could
modulate ATGL levels and thus regulate FA homeostasis. Therefore,
we increased peroxisomal ROS levels by ablation of Cat, which

Fig. 7 | Functions of peroxisomal β-oxidation and ROS in regulating ATGL levels and TAG mobilization in the liver. a, Two weeks after Pex2 knockout
induction, livers were collected and hepatic proteins were analyzed by IB, as indicated (wild-type n = 7; Pex2KO n = 9). b, PEX2–FLAG was expressed for
2 weeks before liver collection and homogenization. IP and IB were conducted using the indicated antibodies. Experiments were repeated four times.
c,d, PEX2–FLAG was expressed in the liver of CatKO or Acox1KO mice. IP and IB were conducted using the indicated antibodies (n = 9 (c); n = 4 (d)).
e, PEX2–FLAG was expressed in the liver of wild-type mice. After 2 weeks, NAC was administered to the mice via intraperitoneal injection at a dose of
500 mg kg−1 body weight for 24 h. IP and IB were conducted using the indicated antibodies (n = 8). f, NAC was administered to the Pex2KO KO mice for
24 h. Livers were collected and hepatic proteins were analysed by IB (n = 5 for Pex2KO for both conditions). g, ATGL levels in human liver biopsies were
analysed by IB and the relative ATGL levels are presented (50 human samples). P = 0.0372 using a Spearman test. h, Wild-type mice with PEX2–FLAG
expression in the liver were challenged with HFD for 16 weeks. IP and IB were conducted using the indicated antibodies (n = 5). i, Wild-type and AtglKO
mice were fed with NCD, HFD and HFD plus NAC (40 mM) in drinking water for 8 weeks. Liver lipids were extracted for TAG level determination (for
wild-type mice, NCD n = 6, HFD n = 7, HFD + NAC n = 7; for AtglKO mice, n = 7). NCD, normal chow diet. j, Representative hematoxylin and eosin staining
images of livers from wild-type or AtglKO mice fed on HFD and NAC-containing water for 8 weeks. Scale bar, 100 μm. Experiments were repeated three
times. k, Working model illustrating the whole pathway in which peroxisomal β-oxidation generates H2O2 to stabilize PEX2 protein, resulting in increased
ATGL degradation and decreased lipolysis in turn. Results are shown as the mean ± s.e.m. analysed using a two-sided Student’s t-test.
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resulted in a decrease in ATGL levels and activity as well as the rate
of lipolysis (Fig. 5a–c and Extended Data Fig. 7a). In contrast, ATGL
protein levels and activity as well as the basal lipolysis rate were elevated after Acox1 ablation (Fig. 5d–f and Extended Data Fig. 7a).
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H2O2 and NAC treatment, ATGL protein levels and activity and
lipolysis rates were decreased by H2O2 (Fig. 5j–l and Extended Data
Fig. 7b) and elevated by NAC (Fig. 5m–o and Extended Data Fig. 7b).
To prove that ATGL regulation in response to changes in peroxisomal ROS levels is dependent on PEX2, we analysed ATGL regulation by Cat siRNA, Acox1 siRNA, VLCFAs, H2O2 and NAC in
the presence and absence of PEX2 and observed that ATGL levels
were insensitive to these treatments in the absence of PEX2, demonstrating the requirement of PEX2 in this process (Extended Data
Fig. 7c–g). We obtained the same results in other cell lines (Fig. 6a–d
and Extended Data Fig. 7h,i), which validates the broad existence of
this functional regulatory mechanisms and underscores its importance for regulating lipid homeostasis in different cell types.
As mitochondria are known to play an important role in FA
oxidation, we investigated whether the interaction of lipolysis and
FA oxidation is an exclusive peroxisomal feature or whether the
paradigm can be extended to mitochondrial β-oxidation. Therefore,
we disrupted mitochondrial FA oxidation in different cell types by
CPT1 and CPT2 ablation and treated cells with the CPT1 inhibitor etomoxir to block mitochondrial FA oxidation. We observed
no changes in ATGL levels after both genetic and pharmacological treatments (Extended Data Fig. 7j–m) and moreover, the
mitochondria-targeted antioxidant MitoQ had no effect on ATGL
levels, suggesting that mitochondrial ROS do not modulate lipolysis
(Extended Data Fig. 7n). Taken together, we demonstrated that ROS
derived from peroxisomal β-oxidation stabilize PEX2, which in turn
leads to increased ATGL degradation and reduced lipolysis thereby
regulating cellular lipid homeostasis.
Origin of FAs as substrates for peroxisomal β-oxidation. It has
been reported that physical interactions between LDs and peroxisomes facilitate lipolysis-derived FA trafficking into peroxisomes16.
Therefore, we hypothesized that the newly discovered mechanism
might provide a direct feedback regulation to control FA supply
via ROS-sensitive PEX2-mediated ATGL degradation. To test this
hypothesis, we repressed lipolysis by ablating ATGL protein expression in different cell lines and observed a reduction of peroxisomal
H2O2 levels and PEX2 protein levels (Extended Data Fig. 8a–c).
In line with this, iBAs stimulated with isoproterenol (Iso) for 24 h
displayed elevated peroxisomal ROS and PEX2 levels, concomitant
with reduced ATGL levels (Fig. 6e,f and Extended Data Fig. 8d,e).
Furthermore, the effects of Iso stimulation were attenuated after
sequestering FAs released from lipolysis by the addition of bovine
serum albumin (BSA)-containing medium (Extended Data Fig. 8f–h).
Together, these data indicate that lipolysis-derived FAs are indeed
substrates of peroxisomal β-oxidation and might thus function as
a feedback regulation to modulate FA release. We further validated
these findings using NBD-C12 to monitor FA trafficking from LDs
to peroxisomes in a pulse-chase experiment, which demonstrated
that blocking lipolysis via non-selective lipase inhibitor (BAY)
reduced FA transfer into peroxisomes (Extended Data Fig. 8i).
To determine whether FAs from other pools could also regulate ATGL levels, we treated cells with lipase (BAY) or esterification (DGAT1i/DGAT2i) inhibitors in the presence of VLCFAs. We
observed that VLCFA addition led to elevated peroxisomal ROS
and reduced ATGL levels, even when lipolysis or esterification of
FAs was blocked (Extended Data Fig. 8j–l), suggesting that under
such conditions exogenous FAs can also be utilized by peroxisomal
β-oxidation and in turn regulate the rate of lipolysis by modulating ATGL levels. Considering that either a lipolysis-derived FA
pool or exogenous FA source is mainly composed of medium- and
long-chain FAs, we further tested the effects of these FAs on ATGL
and lipolysis levels. Therefore, we treated cells with FAs of different carbon lengths and observed that C8:0, C10:0 and C12:0 could
reduce ATGL levels and lipolysis (Fig. 6g–i), coinciding with the
substrate preference of ACOX1 (ref. 2). Taken together, these data
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demonstrate that FAs from either a lipolysis or exogenous source
fuel peroxisomal β-oxidation, which in turn leads to generation of
H2O2 and PEX2 stabilization, which promotes ATGL degradation,
thus maintaining FA homeostasis.
Peroxisome-derived ROS regulate hepatic ATGL levels. As we
demonstrated that peroxisomal ROS levels regulate ATGL protein as well as lipolysis levels in different cell types by modulating
PEX2 stability, we next wanted to extend these data to the in vivo
system to elucidate its physiological relevance. We focused on
the liver because aberrant lipolysis has been reported to promote
non-alcoholic fatty liver disease (NAFLD)29,30. Therefore, we utilized LSL-spCas9 mice to knock out Pex2 in hepatocytes (Pex2KO).
In agreement with our previous data, ATGL protein and activity was substantially upregulated in the liver 2 weeks after Pex2
depletion, independent of changes in the Atgl transcript levels
(Fig. 7a and Extended Data Fig. 9a–d). Moreover, we observed that
hepatic PEX2 displayed an oligomerization pattern, which was
abolished after β-mercaptoethanol (BME) treatment (Fig. 7b),
suggesting the existence of intermolecular and intramolecular
disulfide bonds as well as the sensitivity of these bonds to peroxisomal ROS levels. To modulate specifically peroxisomal ROS levels,
we generated liver-specific Cat and Acox1 knockout mice. In accordance with our in vitro data, we observed that upon hepatic Cat
ablation (CatKO), peroxisomal ROS levels were increased accompanied by an increase in PEX2 and a reduction in ATGL levels (Fig. 7c
and Extended Data Fig. 9e,f). In contrast, in liver-specific Acox1
knockout mice (Acox1KO) we observed reduced peroxisomal ROS
and PEX2 levels and increased ATGL levels (Fig. 7d and Extended
Data Fig. 9g–j), whereas Atgl transcript levels remained unchanged
(Extended Data Fig. 9k).
To analyse whether the effect of peroxisomal ROS on ATGL
regulation was dependent on hepatic PEX2, we used NAC to
modulate ROS levels pharmacologically. We observed reduced
hepatic peroxisomal ROS levels upon acute administration of NAC
for 24 h (Extended Data Fig. 9l); in line with our in vitro data, we
showed that this led to a reduction in hepatic PEX2 levels, which
was concomitant with elevated ATGL levels (Fig. 7e and Extended
Data Fig. 9m), independent of transcriptional changes (Extended
Data Fig. 9n). Furthermore, NAC failed to induce ATGL in the
livers of Pex2KO mice (Fig. 7f), demonstrating that peroxisomal
ROS-dependent PEX2 stabilization is required to regulate ATGL
protein levels in vivo.
Peroxisome-derived ROS regulate hepatic steatosis. It is widely
acknowledged that oxidative stress is elevated in steatotic livers and contributes to the progression of NAFLD31. Therefore, we
next investigated whether peroxisomal ROS levels were elevated
and linked to reduced ATGL levels, which might contribute to the
observed lipid deposition in NAFLD. Therefore, we first analysed
global ROS levels by measuring cysteine sulfenic acid modifications
in human liver biopsies of two NAFLD cohorts and observed a tendency for increased ROS stress in livers with a higher grade of steatosis (Extended Data Fig. 9o). Moreover, we observed a correlation
with ATGL protein levels and grade of steatosis (Fig. 7g), suggesting
that this pathway is altered in NAFLD and might contribute to the
progression of this disease.
To test the importance of this pathway for NAFLD progression,
we challenged mice with a high-fat diet (HFD) to induce hepatic
steatosis. In line with human data, we observed that steatotic livers
displayed increased peroxisomal ROS levels as well as elevated PEX2
levels, whereas ATGL levels were reduced (Fig. 7h and Extended
Data Fig. 9p–r). To test whether modulation of the identified pathway could be used to intervene in the progression of steatosis, we
first analysed hepatic lipid metabolism after knocking out Acox1
and Pex2. We observed upregulation of liver lipolysis, whereas
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global FA oxidation, TG secretion, FA uptake and esterification
remained unaltered (Extended Data Fig. 9s–w). Furthermore, we
induced Cat knockout in murine hepatocytes after 6 weeks on an
obesogenic diet. This intervention led to elevated peroxisomal
ROS levels and induced lipid deposition in the liver (Extended
Data Fig. 10a,b). In contrast, liver-specific Acox1 knockout mice, in
accordance with previous reports32, exhibited a decrease in hepatic
lipid deposition in response to HFD challenge (Extended Data
Fig. 10c,d). To analyse whether observed changes in hepatic lipid
accumulation were due to increased lipophagy, we analysed surrogate markers for lipophagy in our short-term knockout model and
observed no alterations, suggesting a predominant role of lipolysis
in the regulation of steatosis due to changes in peroxisomal ROS
levels (Extended Data Fig. 10e–h). However, the respective contributions of lipolysis and lipophagy regulation in short-term and
long-term knockout models, as well as their possible crosstalk, will
require additional assessments at different time points. To demonstrate whether the protective effect of hepatic ROS reduction is
dependent on lipolysis, we utilized NAC, which has been reported
to alleviate HFD-induced metabolic disorders both in mice and in
patients with NAFLD33,34, albeit through an unknown mechanism.
Therefore, we challenged wild-type mice with an HFD while drinking water was supplemented with NAC. After 8 weeks of treatment,
we observed a significant reduction of hepatic TAG level (Fig. 7i,j).
Notably, NAC failed to alleviate hepatic TAG accumulation in
the absence of ATGL (Atgl KO) (Fig. 7i,j), demonstrating that
NAC-mediated reduction of hepatic TAG accumulation requires
the presence of ATGL. These data demonstrate that ATGL upregulation in the liver due to decreased ROS levels as a result of impaired
peroxisomal β-oxidation or through pharmacological intervention
by NAC promotes mobilization of TAG stores, thus preventing lipid
build-up and progression of steatosis (Fig. 7k).
Due to the complex nature of the identified regulatory process,
our study exhibits several limitations. From published reports10 and
our work it is evident that cellular PEX2 protein levels are strictly
controlled, although this factor is crucial for peroxisome biogenesis and pexophagy. This fact limits the analysis of endogenous
PEX2 levels especially in small biopsy samples. To analyse PEX2
in human steatosis, samples from hepatic surgery might be used
by enriching PEX2 levels via IP. Given the prominent role of peroxisomal FA oxidation, it is interesting to note that it functions as
a sensor to control cellular lipolysis in basal and activated states,
whereas regulation of FA uptake and esterification, triglyceride
secretion and global FA oxidation were not affected. It should be
noted, however, that other metabolic pathways might be regulated
through ROS-mediated PEX2 stabilization as well as the compensation of mitochondrial FA oxidation due to defective peroxisome
function. As mitochondrial FA oxidation accounts for 90% of the
overall FA oxidation capacity3, it is possible that this constitutes the
explanation for why we did not observe any changes when Acox
was ablated in vivo. If PEX2, owing to its tight regulation, is the
responsible E3 ligase, it might be possible to identify other pathways by analysing the substrates of PEX2 in an unbiased manner.
On the other hand, at the molecular level, ATGL protein might be
regulated by other E3 ligases in addition to PEX2 to regulate FA
supply to meet physiological demand.
The process of lipolysis occurs essentially in all cells and tissues
in the body as it provides substrates for energy production and biosynthetic pathways. Here, we provide evidence that peroxisomal
β-oxidation functions as a new sensor of FAs that regulates lipolysis
via an intricate pathway to control ATGL protein levels. Few studies
have hinted at such lipolysis feedback regulation by FAs dating back
to 1965 (ref. 35). It should be noted that the study of such a mechanism is complicated by the fact that FAs via different pathways
can modulate not only gene expression36,37, but also control insulin signalling, which in turn would affect lipolysis by modulating
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HSL activity38. Considering the fact that lipotoxicity is an important factor in the development of metabolic diseases due to uncontrolled lipolysis, the identified crosstalk between peroxisomes and
LDs, which intricately maintains FA levels to meet cellular energy
demands, might be utilized to treat not only NAFLD but also other
metabolic disorders.

Methods

Cell culture and transfection. iBAs were used as described previously39. Once
preadipocytes reached confluence, adipogenesis was induced by differentiation
medium containing 3-isobutyl-1-methylxanthine (500 μM), dexamethasone
(1 μM), insulin (20 nM), T3 (1 nM) and indomethacin (125 μM) for 2 d.
Afterwards, iBAs were kept in maintenance medium containing insulin (20 nM)
and T3 (1 nM). At day 5, differentiated iBAs were replated. All experiments
were routinely performed at day 9. For compound treatment in iBAs, Iso
(Sigma-Aldrich, catalogue no. I5627), H2O2 (Sigma-Aldrich, catalogue no.
216763) and NAC (Sigma-Aldrich, catalogue no. A7250) were added to the
medium at the indicated doses. C2:0 (Sigma-Aldrich, catalogue no. 695092),
C4:0 (Sigma-Aldrich, catalogue no. B103500), C6:0 (Sigma-Aldrich, catalogue
no. 21530), C8:0 (Sigma-Aldrich, catalogue no. O3907), C10:0 (Sigma-Aldrich,
catalogue no. W236403), C12:0 (Sigma-Aldrich, catalogue no. W261408), C14:0
(Sigma-Aldrich, catalogue no. M3128), C16:0 (Sigma-Aldrich, catalogue no.
P0500), C24:0 (Sigma-Aldrich, catalogue no. L6641) and C26:0 (Sigma-Aldrich,
catalogue no. H0388) were all dissolved in ethanol by heating and were added to
the medium at a 100 μM final concentration 48 h before collecting the cells. For
the knockdown experiments, lipofectamine RNAiMAX-mediated siRNA (100 nM)
transfection was performed to knock down target genes on day 6.
HEK293T cells (Abcam, catalogue no. ab255449) were cultured in high-glucose
DMEM with 10% FBS and 1% penicillin/streptomycin. To overexpress human
PEX2/10/12 or ATGL transiently, lipofectamine 2000 was used to deliver plasmids
at 60–80% cell confluence. Cells were treated with 400 μM OA (Sigma-Aldrich,
catalogue no. O1008) to induce LD formation for 24 h. For the knockdown
experiments, siRNAs (100 nM) were transfected using lipofectamine RNAiMAX
reagent for 24 h before LD induction by 400 μM OA-containing medium. After 24 h
of LD induction, cells were collected to analyse endogenous ATGL levels. To knock
down PEX2 in the condition of ATGL–FLAG overexpression, HEK293T cells were
first transfected by plasmids for 12 h, followed by siRNA transfection for 24 h and
LD induction by 400 μM OA-containing medium for 24 h before collecting the
cells. To check ATGL localization in HEK293T cells, plasmids were delivered into
cells and cells were exposed to 400 μM OA-containing medium. One day later,
cells were fixed in 4% PFA for 20 min and stained with HCS LipidTOX Deep Red
Neutral Lipid Stain (Thermo Fisher, catalogue no. H34477) and Hoechst 33342 for
LDs and nuclei labelling, respectively.
HepG2 cells (ATCC, HB-8065) were cultured in RPMI medium with 10%
FBS and 1% penicillin/streptomycin on collagen-coated plates. HepG2 cells
were induced by 400 μM OA to induce LD formation. NAC and H2O2 were
added to the medium at the indicated doses and time points before cell collection.
For the knockdown experiments, lipofectamine RNAiMAX reagent was used
for the transfection of siRNAs (100 nM). All cell lines used in this work were
regularly tested for Mycoplasma contamination. All siRNAs used are listed in
Supplementary Table 1.
Lipolysis measurement. For lipolysis measurement, day 9 iBAs were washed
with pre-warmed PBS and then starved in phenol red-free DMEM medium (low
glucose) with 1% FA-free BSA for 2 h. After medium collection, cells were treated
with 1 μM Iso-containing medium. Glycerol and non-esterified FA release were
measured using Free Glycerol Reagent (Sigma-Aldrich, catalogue no. F6428) and
non-esterified fatty acid (NEFA) assay kit (Wako NEFA kit). Glycerol and NEFA
levels were normalized to protein content.
To measure liver lipolysis, mice were starved for 6 h and dissected. Livers were
cut into pieces (approximately 5 mg per piece) and washed three times with PBS.
Ten liver pieces from one mouse were incubated in 0.5 ml 0.5% BSA containing
RPMI medium (1 g l−1 glucose) for 30 min. Afterwards, liver pieces were incubated
with 0.5 ml 0.5% BSA containing RPMI medium for 30 min. The medium was
collected for glycerol measurements and liver pieces were homogenized in RIPA
buffer for protein quantification.
High-content imaging of adipocytes. Adipocytes cultured in 96-well opaque
black plates were fixed with 4% PFA for 20 min, washed three times with PBS and
stained with Bodipy (Invitrogen) for LDs and Hoechst 33432 (Cell Signaling) for
nuclei. Images were captured via an automated system (Operetta; PerkinElmer)
and analysed using the Harmony software by calculating the ratio of cells with lipid
droplet to the total cell number as described before39.
RNA extraction and quantitative PCR. Total RNA was extracted from liver
samples or in vitro cultured cells using TRIzol reagent (Invitrogen) according to
the manufacturer’s instructions. Genomic DNA was removed from the crude RNA
samples by DNase treatment (New England Biolabs). For individual samples, 1ug
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of total RNA was converted into complementary DNA by using the High-Capacity
cDNA Reverse Transcription Kit (Applied Biosystems, catalogue no. 4368813).
Quantitative PCR was performed using the Fast SYBR Green Master Mix (Applied
Biosystems, catalogue no. 4385618) on ViiA7 (Applied Biosystems) and the relative
transcript levels were normalized to 36B4 expression via the ΔΔCt method. Primer
sequences are listed in Supplementary Table 2.
Virus packaging and stable cell line construction. For lentivirus packaging,
the pLenti-HyPer3-PTS1, pLenti-PEX2–FLAG–EGFP or pLenti-PEX2–FLAG
plasmids were transfected into the 293 LTV cell line (Cell Biolabs) together with
pMD2.G (Addgene, plasmid no. 12259) and psPAX2 (Addgene, plasmid no.
12260) by polyethylenimine in OptiMEM medium. The virus-containing medium
was collected 2 d later and concentrated in PEG-it Virus Precipitation Solution
(SBI, catalogue no. LV825A-1) according to the manufacturer’s instructions. The
concentrated lentiviruses, together with hexadimethrine bromide/polybrene
(Sigma-Aldrich, catalogue no. H9268), were added to the medium to infect iBA
preadipocytes or HepG2 cells, which were selected by 10 μg ml−1 Blasticidin
(Thermo Fisher, catalogue no. A1113903).
For adeno-associated virus (AAV) packaging, we transfected AAV–TBG–Cre,
AAV–TBG–green fluorescent protein (GFP), AAV-U6-NS guide RNA (gRNA)–
TBG–Cre, AAV–U6–Pex2 gRNA–TBG–Cre, AAV–U6–Cat gRNA–TBG–Cre or
AAV–TBG–PEX2–FLAG plasmids into 293 AAV cells (Cell Biolabs) together with
AAV8 serotype helper plasmid (PlasmidFactory, pDP8.ape) using polyethylenimine
in OptiMEM medium. The medium was collected 4–5 d later for concentration
using the AAVanced Concentration Reagent (SBI, AAV110A-1) according to the
manufacturer’s instructions. The titre of concentrated viruses was determined by
quantitative PCR based on the titre determination protocol from Addgene.
Molecular cloning. HyPer3 was cloned from the pAAV-HyPer3 vector (Addgene,
plasmid no. 119183) with a PTS1 sequence in the carboxy terminus and inserted
into a pLenti-CMV-MCS-BSD vector. Human ATGL–FLAG (catalogue no.
RC205708) and PEX2–FLAG–Myc (catalogue no. RC218196) expression plasmids
were obtained from OriGene. To build the lentivirus constructs, human PEX2 was
cloned from PEX2 (catalogue no. RC218196) with a FLAG tag at the C terminus
and inserted into a pLenti-CMV-MCS-BSD vector to obtain the pLenti–PEX2–
FLAG construct. Murine PEX2 was cloned from an iBA cDNA library and inserted
into a pEGFP–N1–FLAG vector (Addgene, plasmid no. 60360). Then PEX2–EGFP
coding sequence (CDS) or PEX2 CDS alone were cloned and inserted into a
pLenti-CMV-MCS-BSD vector to obtain pLenti–PEX2–FLAG–EGFP and pLenti–
PEX2–FLAG constructs. To build an AAV vector for hepatic expression of murine
PEX2–FLAG, murine PEX2 was cloned from a pEGFP–N1–FLAG vector with a
FLAG tag at the C terminus and inserted into pAAV.TBG.PI.eGFP.WPRE.bGH
(Addgene, plasmid no. 105535). For human ATGL lysine-only mutants, we first
obtained the ATGL lysine-null nucleotide sequence from GenScript cloned into a
pEGFP–N1–FLAG vector with a FLAG tag and stop codon at the C terminus. The
Agilent QuikChange II Site-Directed Mutagenesis Kit was used to mutate single
arginine into lysine residues based on the lysine-null ATGL construct. Human
ATGL was cloned from ATGL–FLAG (catalogue no. RC205708) and inserted into
pEGFP–N1–FLAG to obtain the ATGL–EGFP fusion protein. Three lysine residues
in the homeodomain (HD) were mutated to arginine stepwise to obtain ATGL3KR–
EGFP. To build a hydrophobic domain-deficient ATGL, nucleotide sequences
between 1 to 936 and 1,174 to 1,512 were cloned and fused via overlapping PCR
and the fragment was inserted in pEGFP–N1–FLAG to generate ATGLΔHD–EGFP.
For human PEX2 cysteine mutants, individual cysteine residues were mutated to
glycine using PEX2–FLAG–Myc (catalogue no. RC218196). The human PEX2
cysteine-null mutant was synthesized and cloned into a pEGFP–N1–FLAG vector
with a FLAG tag and stop codon at the C terminus. By overlapping PCR, the C
terminus from the wild-type PEX2 and the amino terminus from the cysteine-null
PEX2 were integrated and inserted into a pEGFP–N1–FLAG with a FLAG tag and
stop codon at the C terminus to generate human PEX2C1–7G–FLAG. PEX2C8–
14G–FLAG was constructed likewise. ADRP–EGFP was purchased from Addgene
(plasmid no. 87161). All plasmids for the cell culture work were extracted using
NucleoBond Xtra-Midi Kit (Macherey-Nagel, product no. 740410.100).
Immunoblotting, immunoprecipitation, co-immunoprecipitation and
immunofluorescence. Liver samples, iBAs, HepG2 cells and HEK293T cells were
homogenized in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM
EDTA, 1.0% Triton X-100 and 0.5% sodium deoxycholate) with protease inhibitors
(Roche) and phosphatase inhibitors (Thermo Fisher). The homogenates were
centrifuged at 12,000g for 10 min at 4 °C to remove debris and to collect the whole
cell extract. After boiling the sample with Laemmli buffer at 95 °C for 5 min, equal
amounts of proteins were loaded and separated on a 12% SDS–PAGE. The proteins
were transferred to nitrocellulose membrane or PVDF membrane (Bio-Rad) and
incubated in ATGL (1:1,000 dilution, Cell Signaling), CGI-58 (1:1,000 dilution,
Proteintech), phospho-HSL (Ser660) (1:1,000 dilution, Cell Signaling), PLIN1
(1:1,000 dilution, Cell Signaling), HSL (1:1,000 dilution, Cell Signaling), γ-tubulin
(1:10,000 dilution, Sigma-Aldrich), FLAG (1:10,000 dilution, Sigma-Aldrich ;
1:1,000 dilution, Cell Signaling), PEX10 (1:1,000 dilution, Sigma-Aldrich), PEX12
(1:1,000 dilution, Abcam), CAT (1:1,000 dilution, Cell Signaling), ACOX1 (1:1,000
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dilution, Abcam), phospho-mTOR (Ser2448) (1:1,000 dilution, Cell Signaling),
phospho-S6K (Thr389) (1:1,000 dilution, Cell Signaling), S6K (1:1,000 dilution,
Cell Signaling), LC3 (1:1,000 dilution, Cell Signaling), Calnexin (1:1,000 dilution,
Cell Signaling), PEX2 (1:1,000 dilution, Thermo), EGFP (1:1,000 dilution, Abcam),
COP1 (1:1,000 dilution, Abcam), PMP70 (1:10,000 dilution, Sigma-Aldrich) and
HSP90 (1:1,000 dilution, Cell Signaling) antibodies. The primary antibody signal
was visualized by HRP-conjugated secondary antibodies (1:10,000, Cell Signaling)
and the ImageQuant system (GE Healthcare Life Sciences).
To immunoprecipitate FLAG-tagged ATGL or PEX2, liver samples, iBAs,
HepG2 cells and HEK293T cells were homogenized in RIPA buffer (50 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA and 1.0% Triton X-100) with
protease inhibitors (Roche) and phosphatase inhibitors (Thermo Fisher).
After three washing steps with cold RIPA buffer, 20 μl of anti-FLAG beads
(Sigma-Aldrich, catalogue no. A2220) were added and the mixture was incubated
overnight at 4 °C on a rotator. Beads were washed with cold RIPA buffer six times.
The proteins were eluted by boiling at 95 °C for 5 min in 2× Laemmli buffer. For
the PEX2 polymerization analyses, we used a BME-free Laemmli buffer. The eluted
proteins were analysed by immunoblot (IB) with K48- or K63-linkage-specific
ubiquitin antibodies (1:1,000 dilution, Cell Signaling), HA (1:1,000 dilution, Cell
Signaling), Myc (1:1,000 dilution, Sigma-Aldrich), FLAG (1:1,000 dilution, Cell
Signaling) or ATGL (1:1,000 dilution, Cell Signaling) antibodies.
To immunostain ATGL or PMP70 in iBAs, cells were fixed with 4% PFA for
20 min and permeabilized with 0.25% PBST (Triton X100 in PBS) for 20 min. After
three washes with cold PBS, cells were blocked with 1% BSA for 1 h and incubated
with an ATGL antibody (1:100 dilution, Cell Signaling) or PMP70 antibody (1:100
dilution, Sigma-Aldrich) overnight at 4 °C. After three washes with cold PBS, cells
were incubated with an Alexa Fluor 488- or 568-conjugated secondary antibody
(1:200 dilution, Thermo Fisher) for 1 h at room temperature. Finally, cells were
stained with Hoechst 33342 or LipidTOX Deep Red dye to label nuclei and LDs,
respectively, after being washed three times with PBS to remove residual secondary
antibody. Images were obtained using an Olympus FLUOVIEW 3000 confocal
microscope and processed with ImageJ v.1.53e.
H2O2 measurements. IBAs and HepG2 cells were infected by HyPer3-PTS1
lentivirus and live cells were imaged with an Olympus FLUOVIEW 3000 confocal
microscope. For the reduced form of HyPer3-PTS1, we set excitation at 405 nm and
emission between 510 and 540 nm (F420). For the oxidized form of HyPer3-PTS1,
we set excitation at 488 nm and emission between 510 and 540 nm (F500)24. The
intensity of F420 and F500 was analysed by ImageJ and the F500/F420 ratio
indicated the H2O2 levels.
To analyse peroxisomal H2O2 levels in the murine liver, peroxisomes were
extracted from liver pieces and suspended in RIPA buffer containing 1 mM
dimedone for 30 min40. Non-reducing Laemmli buffer containing 100 mM
maleimide was used to denature peroxisomal proteins for analysis using the
sulfenic acid modified cysteine antibody (1:1,000 dilution, Sigma-Aldrich,
catalogue no. ABS30). The same method was used to analyse cysteine sulfenic acid
modifications of tissue lysate from human liver biopsies treated with dimedone.
Peroxisome extraction. Peroxisomes were extracted from iBAs or HepG2 cells
(3 × 106 cells) following the manufacturer’s protocol (Peroxisome Isolation Kit,
Sigma-Aldrich) for peroxisomal FA oxidation (FAO) and NBD-C12 pulse-chase
experiments. Peroxisomes extracted from 0.5-g liver pieces were used for
peroxisomal FAO and cysteine sulfenic acid modification analysis. For the FAO
and NBD-C12 pulse-chase experiments, the peroxisome fraction extracted
was suspended in peroxisome extraction buffer, whereas RIPA was used to lyse
peroxisomal proteins for cysteine sulfenic acid modification analysis.
FAO measurement. To measure peroxisomal FAO, peroxisomes were extracted
from iBAs, HepG2 cells or livers and suspended in peroxisome extraction buffer
(5 mM MOPS, pH 7.65, 250 mM sucrose, 1 mM EDTA and 0.1% ethanol). The
FAO rate was measured spectrophotometrically41. The reaction was monitored
using a Synergy Gen5 plate reader in a 200-μl system (188 μl of 50 mM Tris-HCl,
pH 8.0, 2 μl 20 mM β-nicotinamide adenine dinucleotide hydrate, 0.6 μl of 0.33 M
dithiothreitol, 1 μl of 1.5% BSA, 1 μl of 2% Triton X-100, 2 μl of 10 mM CoA, 2 μl
of 1 mM flavin adenine dinucleotide disodium salt hydrate, 2 μl of 100 mM KCN,
0.4 μl of 5 mM C12-CoA and 1 μl of peroxisome extract).
To measure global FAO, livers were homogenized in peroxisome extraction
buffer. Then, 30 μl of liver homogenate were added to the 370-μl reaction mixture
(100 mM sucrose, 10 mM Tris-HCl, 5 mM KH2PO4, 0.2 mM EDTA, 80 mM KCl,
1 mM MgCl2, 2 mM l-carnitine, 0.1 mM malate, 0.05 mM CoA, 2 mM ATP, 1 mM
dithiothreitol, 7% BSA, 5 mM palmitate and 0.4 μCi 14C-palmitate) in 1.5-ml tubes
together with an NaOH-containing filter paper disk after 10-min centrifugation at
400g. After 30 min at 37 °C, the filter paper disk was transferred into a scintillation
vial containing 5 ml of scintillation fluid for overnight incubation. The average
counts per minute were measured using a standard scintillation counter.
ATGL lipase activity assay. We used a simplified ATGL activity assay to measure
ATGL activity in iBAs and liver as described, with some modifications42. Briefly,
iBAs or liver pieces were homogenized in assay buffer (50 mM Tris-HCl, pH
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7.4, 150 mM NaCl and 0.1% Triton X-100), followed by sonication for 1 min.
The extract was collected after centrifugation at 12,000g for 10 min. The assay
comprised a 95-μl extract and 5 μl of 2 μM EnzChek Lipase Substrate (Life
Technologies) and was performed in 96-well opaque black plates. The kinetic
liberation rate of the fluorescent product (excitation 485 nm and emission 510 nm)
was monitored using a Synergy Gen5 plate reader. ATGL activity was normalized
to protein levels and presented as the relative value to the control.
NBD-C12 pulse-chase assay. iBAs were treated with 10 mM NBD-C12 to
incorporate the latter into the LDs16. After 24 h, iBAs were washed with PBS to
remove residual NBD-C12 and further cultured in NBD-C12-free medium for
24 h with or without the non-selective lipase inhibitor BAY (CAY10499, Cayman
Chemical). We checked NBD-C12 distribution in peroxisomes and LDs via
imaging or quantification of fluorescence in extracted peroxisomes. Images were
obtained using an Olympus FLUOVIEW 3000 confocal microscope and processed
by ImageJ. After suspending the extracted peroxisomes into peroxisome extraction
buffer, fluorescence (excitation 466 nm and emission 530 nm) was monitored using
a Synergy Gen5 plate reader and presented as the relative values to controls after
normalization to protein levels.
Proximity ligation assay. PEX2–FLAG-expressing iBAs were treated differently,
followed by fixation via PFA for 20 min at room temperature. A proximity ligation
assay was then performed using the kit from Sigma-Aldrich (catalogue no.
DUO92101), following standard protocols with mouse antibody (FLAG, F3165
from Sigma-Aldrich) and rabbit antibody (ATGL, 2138 from Cell Signaling)
incubation or incubation without antibodies as the negative control. Images were
obtained using an Olympus FLUOVIEW 3000 confocal microscope and processed
with ImageJ.
Patient liver biopsies. Human liver biopsies were collected in two cohorts
and were analysed for data integration. The liver biopsies of one cohort were
obtained during the work-up of liver disease diagnostics in the outpatient clinic
of the Division of Gastroenterology and Hepatology, University Hospital Basel,
Switzerland. The study was carried out in accordance with the Code of Ethics of
the World Medical Association (Declaration of Helsinki 2013, seventh revision)
and was approved by the local ethics committee (EKNZ 2014-362). Written
informed consent was obtained from all patients. Five to ten millimeters of liver
biopsy cylinders were immediately snap-frozen by immersion in liquid nitrogen
and stored in liquid nitrogen vapours until processing. The human liver biopsies
of the second cohort were obtained from participants of the Biological Atlas of
Severe Obesity cohort, an ongoing prospective cohort study for the longitudinal
assessment of metabolic outcomes after weight loss surgery (NCT01129297),
which was approved by the CHRU Lille Ethical committee and were compliant
with French National Ethics Committee guidelines. The study design has been
described previously in detail43. Clinical patient information is described in
Supplementary Table 3.
Mouse experiments. All animal experiments were approved by the veterinary
office of the Canton of Zurich. The mice used in the experiments were housed
2–5 littermates per cage in ventilated cages under standard housing conditions
(22 °C, 40% humidity, 12-h reversed light–dark cycle, the dark phase starting at
7:00) with ad libitum access to NCD (18% protein, 4.5% fiber, 4.5% fat and 6.3%
ashes, Provimi-Kliba) and water. The health status of all mice was monitored
regularly based on the Federation of European Laboratory Animal Science
Associations guidelines. The 8–10-week-old female C57BL/6 and liver-specific
Pex2 overexpression or knockout mice were subjected to NAC administration
(500 mg kg−1 body weight) via intraperitoneal injection. After 24 h, mice were killed
for liver collection. To express FLAG-tagged murine PEX2 in the liver, AAV–TBG–
GFP or AAV–TBG–PEX2–FLAG viruses were injected into mice via tail veins at
a dose of 3 × 1011 genome copies per mouse. To knock out Pex2 specifically in the
liver, ROSA26-LSL-spCas9 mice (The Jackson Laboratory strain) were injected
with AAV–U6–NS gRNA–TBG–Cre, AAV–U6–Pex2 gRNA–TBG–Cre or AAV–
U6–Cat gRNA–TBG–Cre virus pools to express six Pex2 gRNAs or Cat gRNAs in
conjunction with CAS9 in the liver. To knock out Acox1 specifically in the liver,
we utilized Acox1 floxed mice19. The Acox1 floxed mice were injected with AAV–
TBG–Cre virus. For HFD, NAC was administered to C57BL/6 mice in drinking
water (40 mM) for 8 weeks. For liver-specific Atgl knockout mice, Atgl floxed
mice (The Jackson Laboratory strain)44 were injected with AAV–TBG–Cre virus.
Afterwards mice were challenged with an HFD- and NAC-containing drinking
water for 8 weeks. Acox1 or Cat liver-specific knockout mice were challenged by
HFD for 6 weeks first and injected with virus to induce knockout and kept for 2
weeks on an HFD. Overall, all HFD experiments were performed after 8 weeks
of HFD feeding, whereas experiments on NCD were carried out for 2 weeks after
virus injection or 24 h after acute NAC injection. Before tissue collection, all mice
were starved for 6 h.
Liver TAG determination. The weight of liver pieces (50–100 mg) was recorded
before homogenization by 1 ml of chloroform:methanol (2:1) per 50 mg tissue.
Homogenates were incubated at room temperature on a rotator before spinning
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to remove debris at 600g for 5 min. Then, 200 μl of saline per 50 mg of tissue was
added, followed by vortexing and centrifugation at 400g for 5 min. The lower phase
was dried after removing the upper phase. The lipids were suspended in 2% Triton
X-100 solution with sonication. The TAG levels were determined (Roche Trig/GB
reagent) and normalized to the weight of the liver pieces.
Haematoxylin and eosin staining. Livers were fixed in 4% PFA in PBS for 24 h
directly after tissue collection. Liver pieces were transferred to 65% ethanol and
embedded in paraffin in a tissue-processing and embedding machine, followed by
sectioning at 10 μm and staining with hematoxylin and eosin.
Liver TG secretion, FA uptake and esterification. Mice were starved for 6 h
and blood was sampled before tyloxapol (80 mg ml−1) administration via the tail
vein. After 4 h, blood was sampled again. Alterations of plasma TAG levels were
measured (Roche Trig/GB reagent) to calculate the TAG secretion rate.
Mice were injected with BODIPY-palmitate (10 μg per mouse) via the tail vein.
At 30 min after injection, livers were dissected for homogenization in RIPA buffer.
The BODIPY fluorescence of the homogenate was measured using a Synergy Gen5
plate reader and normalized to protein levels.
For FA esterification determination, 1 h after BODIPY-palmitate injection,
livers were dissected for LD extraction. The fluorescence intensity of the extract
was measured and normalized to the TAG levels of the LDs to calculate the
esterification rate.
Quantification and statistical analysis. For the in vivo studies, littermates were
randomly assigned to treatment groups for all experiments. Sample size was
determined based on previous experiments and the animal numbers used in
the experiments are indicated in the corresponding figure legends. For the cell
culture experiments, at least three technical replicates were used. Results are
presented as the mean ± s.e.m. A two-tailed unpaired Student’s t-test was applied
to comparisons of two groups. Analysis of variance (ANOVA) was applied to
comparisons of multiple groups using a Dunnett correction post-hoc analysis. A
non-parametric Spearman test was used for the correlation analysis. All statistical
analyses were performed using GraphPad Prism 7 software. Statistical differences
are indicated as exact P values.
Reporting Summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.

Data availability

All raw data are available and provided as resource data. Source data are provided
with this paper.
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Extended Data Fig. 1 | See next page for caption.
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Extended Data Fig. 1 | PEX2/10/12 downregulation increases iBAs lipolysis without effects on differentiation levels. (a) Quantification of peroxisomes
in the proximity to LDs and LDs in proximity to peroxisomes in iBAs at basal state and stimulated state (peroxisome quantification, cell number = 10; LD
quantification, cell number = 14 in control and 15 in Iso treatment). LD labelled by LipidTOX Deep Red dye (red) and peroxisomes labelled by EGFP-PTS1
(green). Scale bar, 5 μm. (b) Quantification of peroxisomes in the proximity to LDs in HepG2 cells (Cell number = 15). LD labelled by LipidTOX Deep Red
dye (red) and peroxisomes labelled by EGFP-PTS1 (green). Scale bar, 10 μm. (c) Differentiation and screening strategy in iBAs. A pool of three different
duplexes was utilized to knock down individual PEX target. (d-e) IBAs were transfected with siRNAs to knock down Pex2/10/12. After 72 h, lipolysis was
determined as level of glycerol and NEFA released into starvation medium during 2 hours at basal state and 1 hour at stimulated state induced by 1 μM Iso
(N = 5, F = 21.58 in basal state and 15.38 in stimulated state in d; F = 11.81 in basal state and 8.797 in stimulated state in e). (f-h) IBAs were transfected
with siRNAs to knock down Pex2/10/12. After 72 h, Pex2/Pex10/Pex12, Pparg2 and Adipoq transcripts were quantified by qPCR (N = 3). (i) IBAs were
transfected with siRNAs to knock down Pex2/10/12. After 72 h, levels of adipocyte differentiation were determined via high-content imaging (N = 6,
F = 4.51). (j) IBAs were transfected with siRNAs to knock down Pex2/10/12. After 72 h, cells were stained by Oil Red O and the latter was extracted by
isopropanol for quantification (N = 3, F = 1.816). (k-l) IBAs were transfected with siRNAs to knock down Pex2. After 72 h, peroxisome mass was analyzed
by IB or IF via peroxisomal membrane protein PMP70 (N = 4 in Pex2 and 8 in Nc siRNA, F = 22.61). Scale bar, 40 μm. Repeated 3 times in l. (m) IBAs were
transfected with siRNAs to knock down Pex10/12. After 72 h, peroxisome mass was analyzed by IB as indicated. Repeated 3 times. Results are shown as
mean ± SEM and analyzed using Student’s two-sided t test (a) and an ANOVA test with Dunnett correction for multiple comparisons between control and
other groups (d-k).

Nature Metabolism | www.nature.com/natmetab

Articles

NATuRE METAbOLISm

Extended Data Fig. 2 | See next page for caption.
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Extended Data Fig. 2 | PEX2/10/12 downregulation increases ATGL protein levels independently of transcription modulation. (a-b) IB of endogenous
HSLSer660ph, HSL, ATGL, CGI-58, PLIN1 and γ-tubulin in iBAs 72 h after knockdown of Pex10/12 (N = 6 in Pex10/12 and 12 in Nc siRNA, F = 36.91 in a and 42.4
in b). (c) Representative IF of ATGL in iBAs 72 h after knockdown of Pex10/12. ATGL in red, LDs in green and nuclei in blue. Scale bar, 20 μm. Repeated 4
times. (d) IBAs were transfected with siRNAs to knock down Pex2. After 72 h, ATGL lipase activity assay was conducted using the WCE (N = 4). (e) IBAs
were transfected with siRNAs to knock down Pex2/10/12. After 72 h, qPCR was conducted to check Atgl transcript (N = 4 in Pex2/10/12 and 5 in Nc siRNA,
F = 3.853). (f) IBAs were transfected with Pex5 and Pex19 siRNAs. After 72 h, IB was conducted to check protein levels by indicated antibodies. (g) Human
PEX2 knockdown efficiency was validated by qPCR 48 h after HepG2 cells were transfected with PEX2 siRNAs (N = 3, F = 94.61). (h-i) HepG2 cells were
transfected with PEX10/12 siRNAs for human PEX10 and PEX12 antibodies validation by IB (N = 4). (j) IB of ATGL and γ-tubulin in HepG2 cells 48 h after
knockdown of PEX10/12 (N = 6 in PEX10/12 and 12 in Nc siRNA, F = 26.32). (k) HepG2 cells were transfected with PEX5 and PEX19 siRNAs. After 72 h, IB
was conducted to check protein levels by indicated antibodies. (l) HepG2 cells were transfected with siRNAs to knock down PEX2/10/12. After 48 h, qPCR
was conducted to quantify ATGL transcript (N = 3, F = 0.1052). (m) IB of ATGL and γ-tubulin in HEK293T cells 48 h after knockdown of PEX10/12 (N = 4
in PEX10/12 and 6 in Nc siRNA, F = 0.3977). (n) IB of ectopically expressed ATGL-FLAG and γ-tubulin in HEK293T cells 48 h after knockdown of PEX10/12
(N = 4 in PEX10/12 and 8 in Nc siRNA, F = 0.6143). (o) PEX2/10/12 knockdown efficiency was determined by qPCR 48 h after transfecting HEK293T cells
by siRNAs (N = 3). (p) HEK293T cells were transfected with siRNAs to knock down PEX2. After 72 h, cells were fixed for LDs staining. LDs are marked in
green and nuclei in blue. Scale bar, 20 μm. Repeated 4 times. Results are shown as mean ± SEM and analyzed using Student’s two-sided t test (d, h, i) and
an ANOVA test with Dunnett correction for multiple comparisons between control and other groups (a, b, e, g, j-o).
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Extended Data Fig. 3 | PEX2 and ATGL proteins interact physically. (a) Co-IP conducted in HEK293T WCE via FLAG antibody 48 h after expressing
PEX2-FLAG. Co-IP was analyzed by IB using indicated antibodies. Repeated 3 times. (b) Co-IP conducted in HEK293T WCE via FLAG antibody 48 h
after expressing indicated constructs. Co-IP was analyzed by IB using indicated antibodies. Repeated 3 times. (c) Direct interaction of ATGL and PEX2
in PEX2-FLAG-EGFP expressing iBAs was checked via proximity ligation assay (PLA) at different conditions. Upper panel represents the PEX2 and ATGL
interaction. Lower panel is the nuclei (blue) merged with interaction intensity between PEX2 and ATGL. Repeated 3 times. (d) Positions of lysine residues
and hydrophobic domain (HD) in human ATGL protein. Three lysine residues with strikethrough are not conserved in murine ATGL.

Nature Metabolism | www.nature.com/natmetab

NATuRE METAbOLISm

Articles

Extended Data Fig. 4 | PEX2 ubiquitinates ATGL via K48-linkage poly-ubiquitination to promote its degradation in HEK293T cells. (a) ATGL lysine-only
mutants were overexpressed in HEK293T cells. After 36 h, cells were treated by 10 μM MG132 for 8 h. IB was conducted to analyze protein levels after
blocking proteasome dependent degradation. Repeated 2 times. (b) ATGL lysine-only mutants were overexpressed in HEK293T cells, followed by PEX2
siRNA transfection. After 48 h, IB was conducted to determine protein levels. Repeated 2 times. (c) HEK293T cells were transfected by ATGLK0-FLAG
or ATGLK92-FLAG plasmids, followed by siRNA transfection for 48 h. IB was conducted to analyze protein levels of ATGLK0-FLAG and ATGLK92-FLAG
(ATGLK0-FLAG, N = 4 in PEX2 and 8 in Nc siRNA, F = 0.9678; ATGLK92-FLAG, N = 5 in PEX2 and 10 in Nc siRNA, F = 15.26). (d) ATGL ubiquitination was
analyzed via IP and IB after stimulating ATGL-FLAG expressing iBAs with Iso. Repeated 3 times. (e) IBAs were fractionated to collect different fractions for
protein analysis using indicated antibodies. Repeated 3 times. (f) ATGL-FLAG expressing iBAs were fractionated to collect LDs for IP and IB by indicated
antibody. The K48-linkage poly-ubiquitination level of LD associated ATGL was analyzed from iBAs at both basal state and activated state induced by 1 μM
Iso. Repeated 3 times. (g) ATGL-FLAG expressing iBAs were fractionated to collect cytosol fraction for IP and IB by indicated antibody. Repeated 3 times.
(h) HEK293T cells were transfected by ADRP-EGFP plasmid, followed by PEX2 siRNA transfection. After 48 h, IP and IB were conducted by indicated
antibody to check K48-linkage poly-ubiquitination level. Repeated 3 times. Results are shown as mean ± SEM and analyzed using an ANOVA test with
Dunnett correction for multiple comparisons between control and other groups.
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Extended Data Fig. 5 | ROS regulates PEX2 protein levels. (a) Colocalization analysis of HyPer3-PTS1 with peroxisome marker (PMP70) and LDs in
iBAs. Scale bar, 10 μm. Repeated 3 times. (b) Peroxisomal H2O2 levels were measured in HepG2 cells 48 h after CAT and ACOX1 siRNA transfection via
HyPer3-PTS1 (Cell number = 20, F = 27.56). (c) Peroxisomes were extracted from HepG2 cells after ACOX1 protein depletion to measure peroxisomal
fatty acid oxidation activity (N = 4). (d) Peroxisomal H2O2 levels were measured in HepG2 cells 24 h after NAC treatment or 30 min upon H2O2 addition
via HyPer3-PTS1 (Cell number = 23, F = 121.4). (e-f) HepG2 cells were treated with 1 mM H2O2 and harvested at indicated time points. IP and IB were
conducted with indicated antibodies. Repeated 3 times. (g) Peroxisomal H2O2 levels were measured in iBAs cells after Cat and Acox1 siRNAs transfection
via HyPer3-PTS1 (Cell number = 18 in Acox1 and 29 in Cat&Nc siRNA, F = 78.36). (h) Peroxisomes were extracted from iBAs after ACOX1 protein depletion
to measure peroxisomal fatty acid oxidation activity (N = 4). (i-j) Peroxisomal H2O2 levels were measured in iBAs via HyPer3-PTS1 sensor after 0.5 mM
H2O2, 100 μM C26:0, 100 μM C24:0 and 3 mM NAC treatment (i, cell number = 15 in H2O2 treatment and 23 in control; j, cell number = 24, F = 93). (k)
HEK293T cells were transfected with plasmids to overexpress PEX2-FLAG, PEX10-HA and PEX12-HA. After 48 h, cells were treated by 0.5 mM H2O2 and
harvested at indicated time points for IB via indicated antibodies. Repeated 3 times. (l-m) IBAs were treated with 0.5 mM H2O2 at indicated time points.
Peroxisome mass was analyzed by IB or IF via PMP70. Scale bar, 40 μm. Repeated 3 times. (n) HEK293T cells were transfected with PEX2-FLAG plasmid.
After 48 h, cells were treated by 0.5 mM H2O2 in the presence of 100 μg/ml CHX to check PEX2 degradation rate via IB. Repeated 3 times. Results are
shown as mean ± SEM and analyzed using Student’s two-sided t test (c, h, i) and ANOVA test with Dunnett correction for multiple comparisons between
control and other groups (b, d, g, j).
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Extended Data Fig. 6 | See next page for caption.
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Extended Data Fig. 6 | ROS promotes PEX2 stability via disulfide bonds. (a) IBAs expressing PEX2-FLAG-EGFP were collected for IP and IB by
indicated antibodies. Repeated 3 times. (b) Human PEX2 was overexpressed in HEK293T cells. After treatment by 10 μM MG132 for 6 h, IP and IB were
conducted to analyze PEX2 oligomerization pattern by indicated antibodies. Repeated 3 times. (c) Single cysteine to glycine mutants of human PEX2
were overexpressed in HEK293T cells. IP and IB were conducted to analyze their oligomerization patterns by indicated antibodies. Repeated 2 times. (d)
Single cysteine to glycine mutants of human PEX2 were overexpressed in HEK293T cells. Cells were treated with 0.5 mM H2O2 for 2 h. IP and IB were
conducted to analyze PEX2-FLAG-Myc protein by indicated antibodies. Repeated 2 times. (e-f) Wild type PEX2 or PEX2 mutants (siRNA resistant)
were overexpressed in HEK293T cells or co-expressed with ATGL-FLAG, followed by siRNAs transfection. IP and IB were conducted using the indicated
antibodies. Repeated 3 times. (g) PEX2 and PEX2C1-7G mutant were overexpressed in HEK293T cells, followed by 0.5 mM H2O2 treatment for 2 h. IP and
IB were conducted to check K48-linkage poly-ubiquitination level. Repeated 3 times. (h-i) IBAs were transfected with Cop1 siRNAs or treated by 0.5 mM
H2O2 and harvested at the indicated time points. IB was conducted using the indicated antibodies (h, N = 4 in Cop1 and 10 in Nc siRNA, F = 2.544; i, N = 3
in H2O2 treatment and 9 in control, F = 0.9765). Results are shown as mean ± SEM and analyzed using an ANOVA test with Dunnett correction for multiple
comparisons between control and other groups.
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Extended Data Fig. 7 | See next page for caption.
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Extended Data Fig. 7 | Peroxisomal β-oxidation and ROS levels regulate ATGL levels and lipolysis. (a) 72 h after knocking down Cat and Acox1 in
iBAs, ATGL lipase activity assays were conducted using the WCE (N = 4, F = 70.21). (b) IBAs were treated with 0.5 mM H2O2 for 9 h or 2 mM NAC for
24 h. ATGL lipase activity assays were conducted using the WCE (N = 4, F = 43.33). (c-g) IBAs were transfected with Nc and Pex2 siRNAs. Under this
background, cells were treated with Cat siRNA, Acox1 siRNA, 100 μM C26:0 and C24:0, 0.5 mM H2O2 or 2 mM NAC, as indicated. IB was conducted to
check protein levels by indicated antibodies (f, N = 3 in H2O2 treatment and 6 in control; N = 4 in c, d, e, g; F = 13.29 in Nc and 0.08457 in Pex2 siRNA in
c; F = 119.5 in Nc and 0.06723 in Pex2 siRNA in d; F = 16.26 in Nc and 0.214 in Pex2 siRNA in e). (h) PEX2-FLAG and ATGL-FLAG were co-transfected in
HEK293T cells. After 48 h, cells were treated by 0.5 mM H2O2 and harvested at indicated time points. IB was conducted by indicated antibodies. Repeated
3 times. (i) Wild type PEX2 and PEX2C1-7G (siRNA resistant) were expressed in HEK293T cell under the background of endogenous PEX2 depletion. After
48 h, cells were treated by 0.5 mM H2O2 and harvested at indicated time points. IB was conducted by indicated antibodies. Repeated 3 times. (j) IBAs
were transfected with Cpt1b and Cpt2 siRNAs to inhibit mitochondrial fatty acid oxidation. After 72 h, IB was conducted to check protein levels by indicated
antibodies (N = 4 in Cpt1b&Cpt2 and 8 in Nc siRNA, F = 0.125). (k) IBAs were treated with mitochondrial fatty acid oxidation inhibitor etomoxir (ETO) at
indicated time points. IB was conducted to check protein levels by indicated antibodies (N = 3 in ETO treatment and 9 in control, F = 1.016). (l) HepG2
cells were transfected with CPT1A and CPT2 siRNAs to inhibit mitochondrial fatty acid oxidation. After 72 h, IB was conducted to check protein levels by
indicated antibodies (N = 4 in CPT1A&CPT2 and 8 in Nc siRNA, F = 0.3906). (m) HepG2 cells were treated with mitochondrial fatty acid oxidation inhibitor
ETO at indicated time points. IB was conducted to check protein levels by indicated antibodies (N = 3 in ETO treatment and 9 in control, F = 0.3629).
(n) IBAs were treated with mitochondria targeted antioxidant MitoQ at indicated doses for 24 h. IB was conducted to check protein levels by indicated
antibodies (N = 4, F = 0.7356). Results are shown as mean ± SEM and analyzed using Student’s two-sided t test (g) and ANOVA method with Dunnett
correction for multiple comparisons between control and other groups (a-f, j-n).
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Extended Data Fig. 8 | Lipolysis provides substrates for peroxisomal β-oxidation. (a-b) Peroxisomal H2O2 levels in HepG2 cells and differentiated iBAs
were quantified by HyPer3-PTS1 after ATGL depletion by siRNA (a, cell number = 37 in ATGL and 47 in Nc siRNA; b, cell number = 18 in Atgl and 25 in
Nc siRNA). (c) IBAs with PEX2-FLAG-EGFP expression were treated with Atgl siRNA and harvested 72 hours after transfection. IP and IB were conducted
using the indicated antibodies (N = 4). (d) Peroxisomal H2O2 levels in differentiated iBAs were quantified by HyPer3-PTS1 6 hours after Iso treatment (cell
number = 22). (e) IBAs were stimulated with Iso for 24 h at indicated doses. Atgl transcript was quantified by qPCR (N = 4, F = 7.57). (f) Peroxisomal H2O2
levels in differentiated iBAs were quantified by HyPer3-PTS1 6 hours after Iso treatment in the presence of 5% BSA (cell number = 16 in Iso treatment and
17 in control). (g) IBAs with PEX2-FLAG-EGFP expression were treated with 0.1 μM Iso in the presence of 5% BSA and harvested at the indicated time
points. IP and IB were conducted using the indicated antibodies (N = 4). (h) IBAs were treated with 0.1 μM Iso in the presence of 5% BSA and harvested at
indicated time points. IB were conducted using the indicated antibodies (N = 4). (i) Pulse-chase experiments to monitor NBD-C12 (green) trafficking from
LD to peroxisome in iBAs. IBAs transfected with mCherry-PTS1 were pulsed with 10 μM NBD-C12 for 24 h, followed by lipolysis inhibitor treatment (BAY)
after washing. 24 h later, cells were fixed for imaging or collected for fractionation and fluorescence measurement (N = 5). LDs were labelled by LipidTOX
Deep Red dye. Scale bar, 5μm. Repeated 3 times. (j-l) IBAs were treated by 100 μM C26:0 and C24:0 for 48 h in the presence of lipolysis inhibitor (BAY)
or DGAT1/2 inhibitors. Peroxisomal ROS levels were measured (cell number = 58, F = 15.71) or IB was conducted to check protein levels by indicated
antibodies (N = 4; F = 15.59 in DMSO and 7.561 in BAY treatment of k; F = 16.68 in DMSO and 9.005 in DGAT1/2i treatment of l). Results are shown as
mean ± SEM and analyzed using Student’s two-sided t test (a-d, f-i) or an ANOVA test with Dunnett correction for multiple comparisons between control
and other groups (e, j-l).
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Extended Data Fig. 9 | See next page for caption.
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Extended Data Fig. 9 | Functions of peroxisomal β-oxidation and ROS in regulating ATGL levels in liver. (a-b) Pex2 transcript in the liver and adipose
tissue of liver-specific Pex2 knockout mice (Pex2KO) was quantified by qPCR (N = 5). (c) Atgl transcript in Pex2 knockout liver was quantified by qPCR
(WT N = 7; Pex2KO N = 9). (d) ATGL lipase activity was measured using the liver lysate from Pex2KO mice (N = 7). (e) Hepatic peroxisomes were
extracted from the liver-specific Cat knockout mice to determine cysteine sulfenic acid modification levels of peroxisomal proteins. Repeated 3 times.
(f) ROSA26-LSL-spCas9 mice were injected with a pool of AAV to express Cat gRNA in the liver. After 2 weeks, ATGL protein levels were analyzed by
indicated antibodies (N = 6). (g) Acoxfl/fl mice were injected with AAV-TBG-Cre virus to ablate hepatic Acox1 (Acox1KO). After 2 weeks, peroxisomal
β-oxidation was measured using peroxisomes from livers (N = 5). (h) Hepatic peroxisomes were extracted from the liver specific Acox1 knockout mice
to determine cysteine sulfenic acid modification levels of peroxisomal proteins. Repeated 3 times. (i) After harvesting liver from Acox1KO mice, hepatic
ATGL levels were checked by IB with indicated antibodies (N = 6). (j) ATGL lipase activity was measured using the liver lysate from Acox1KO mice (N = 6).
(k) Atgl transcript in Acox1 knockout liver was quantified by qPCR (N = 6). (l) Peroxisomes were extracted from the livers of mice following acute NAC
administration to determine cysteine sulfenic acid modification levels of peroxisomal proteins. Repeated 3 times. (m) NAC was administered acutely by
intraperitoneal injection into wild type mice at dosage of 500 mg/kg BW. Hepatic ATGL levels were checked by IB with indicated antibodies (Saline N = 15;
NAC N = 17). (n) Quantification of Atgl transcript in the livers of mice following acute NAC administration (Saline N = 11; NAC N = 13). (o) Cysteine sulfenic
acid modification in human liver biopsies was analyzed by IB and relative levels of cysteine sulfenic acid modification are presented (50 human samples
with different steatosis levels). P = 0.0005 by Spearman test for correlation analysis. (p) Hepatic peroxisomes were extracted from the 14 weeks HFD
challenged mice to determine cysteine sulfenic acid modification levels of peroxisomal proteins. Repeated 3 times. (q) After challenging mice with HFD for
16 weeks, hepatic ATGL protein levels were analyzed by indicated antibodies (NCD N = 10; HFD N = 9). (r) Atglfl/fl mice were injected with AAV-TBG-Cre
virus to knock out Atgl in liver. After 2 weeks, hepatic peroxisomes were extracted from these mice to determine cysteine sulfenic acid modification levels
of peroxisomal proteins. Repeated 3 times. (s) Fatty acid oxidation was measured in liver homogenate from Acox1KO and Pex2KO mice using 14C-labelled
palmitate as substrate (N = 6). (t) Ex vivo lipolysis was determined via the measurement of glycerol released from liver pieces dissected from Acox1KO and
Pex2KO mice (N = 6). (u) Rates of TG secretion from the livers of Acox1KO and Pex2KO mice were determined by plasma triglyceride accumulation within
4 hours after tail vein injection of tyloxapol (N = 5). (v) Fatty acid uptake rate in the livers of Acox1KO and Pex2KO mice was determined via fluorescence
measurement in the liver extracts 30 min after tail vein injection of Bodipy-palmitate at the dose of 10 μg/mouse (N = 5). (w) Fatty acid esterification rate
in the livers of Acox1KO and Pex2KO mice was determined via fluorescence measurement in the liver lipid droplet fraction 1 h after tail vein injection of
Bodipy-palmitate at the dose of 10 μg/mouse (N = 5). Results are shown as mean ± SEM and analyzed using a Student’s two-sided t test.
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Extended Data Fig. 10 | Functions of peroxisomal β-oxidation and ROS in regulating TAG mobilization in liver. (a) ROSA26-LSL-spCas9 mice were
injected with a pool of AAV to express Cat gRNA in the liver. After 2 weeks on NCD or 8 weeks on HFD, hepatic lipids were extracted for TAG content
determination (NCD N = 5 in both genotypes; HFD N = 7 in both genotypes). (b) Representative H&E staining images of livers from liver specific Cat
knockout mice fed on NCD or HFD for 8 weeks. Scale bar, 100μm. Repeated 3 times. (c) Acox1fl/fl mice were injected with AAV-TBG-Cre virus to knock out
Acox1 in the liver. After 2 weeks on NCD or 8 weeks on HFD, hepatic lipids were extracted for TAG content determination (NCD N = 6 in both genotypes;
HFD WT N = 8 and Acox1KO N = 9). (d) Representative H&E staining images of livers from liver specific Acox1 knockout mice fed on NCD or HFD for 8
weeks. Scale bar, 100μm. Repeated 3 times. (e-h) Lipophagy/autophagy in the livers was analyzed via IB using surrogate autophagy markers, as indicated.
Repeated 3 times. Results are shown as mean ± SEM and analyzed using a Student’s two-sided t test.
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Data collection

No specific software was used

Data analysis

ImageJ (version 1.53e) was used to analyze western blots and images. Graphpad prism (version 9.1) was used to perform statistical analyses.
Harmony 3.5 was used in high content adipocyte differentiation determination
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Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size

Sample sizes were determined on the basis of previous experiments using similar methods (ref. 39).

Data exclusions

No samples were excluded from any analyses.

Replication

Experimental findings were verified by biological replicates and technical replicates, each experiment was performed multiple times as
indicated in the figure legends.

Randomization

All experiments were randomized

Blinding

The investigators were not blinded to the mice as they themselves were treating and sacrificing the mice. However, the investigators were
blinded for sample processing.
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ChIP-seq

Eukaryotic cell lines

Flow cytometry

Palaeontology and archaeology

MRI-based neuroimaging

Animals and other organisms
Human research participants
Clinical data
Dual use research of concern

Antibodies
ATGL (1:1000, Cell Signaling:2138S), CGI-58 (1:1000, Proteintech:12201-1-AP), phosphor-HSL(Ser660) (1:1000, Cell Signaling:45804S),
PLIN1 (1:1000, Cell Signaling:9349S), HSL (1:1000, Cell Signaling:4107S), γ-tubulin (1:10000, Sigma:T6557), FLAG (1:10000,
Sigma:F3165; 1:1000, Cell Signaling:2368S), PEX10 (1:1000, Sigma:WH0005192M1), PEX12 (1:1000, Abcam:ab103456), CAT (1:1000,
Cell Signaling:14097S), ACOX1 (1:1000, Abcam:ab184032), HSP90 (1:1000, Cell Signaling:4877S), K48 or K63 linkage specific ubiquitin
antibody (1:1000, Cell Signaling:33959), HA (1:1000, Cell signaling:3724S), Myc (1:1000, Sigma:C3956), PMP70 antibody (1;10000,
Sigma:SAB4200181), PEX2(1:1000, Thermo:PA5-26187), Calnexin (1:1000, Cell signaling:2433S), EGFP(1:1000, Abcam:ab290),
Cysteine sulfenic acid (1:1000, Sigma:ABS30), p-mTORSer2448(1:1000, Cell signaling:2974S), p-S6KThr389(1:1000, Cell
signaling:9205S), S6K(1:1000, Cell signaling:9202S), LC3 (1:1000, Cell signaling:2775S), COP1(1:1000, abcam:ab56400), HRPconjugated anti-rabbit IgG (1:10000, Cell signaling: 7074), HRP-conjugated anti-mouse IgG (1:10000, Cell signaling: 7076),Goat antiRabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 568 (1:200, Thermo:A11011),Donkey anti-Mouse IgG (H+L) Highly
Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 (1:200, Thermo:A21202)

Validation

We validated ATGL,ACOX1 and CAT antibodies in both mouse and human cell lines for WB application via siRNA knockdown.
We validated PEX10, PEX12 antibodies in human cell line for WB application via siRNA knockdown.
We validated COP1 antibodies in mouse cell line for WB application via siRNA knockdown.
The following antibodies were validated by previous publications, ATGL(10.7554/eLife.63665),CGI-58 (10.1038/s42255-019-0066-3),
PLIN1 (10.1172/jci.insight.139160), HSL (10.1172/jci.insight.139160), K48 or K63 linkage specific ubiquitin antibody (10.1038/
s41419-020-03299-8), PMP70 (10.1038/ncb3230), Calnexin (10.1111/acel.13368), HSP90 (10.1371/journal.ppat.1009582),pmTORSer2448, LC3 (https://doi.org/10.1016/j.molcel.2020.05.007), p-mTORSer2448 (https://doi.org/10.1016/j.molcel.2020.05.007),
S6K (https://doi.org/10.1016/j.molcel.2020.05.007), p-S6KThr389 (https://doi.org/10.1016/j.molcel.2020.05.007), Cysteine sulfenic
acid (10.1371/journal.pone.0180455),EGFP (10.1080/15548627.2020.1740529), Myc (10.1016/j.cell.2008.08.036), HA (10.1038/
s41467-021-24097-6)
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Policy information about cell lines
Cell line source(s)

293-AAV and 293-LTV cell lines were purchased from Cell Biolabs Inc. (cat. AAV-100; LTV-100); HEK293T cell line was
purchased from abcam. iBAs cells were previously established by Ronald Kahn lab as indicated in manuscript. HepG2 cells
were purchased from ATCC.

Authentication

293-AAV and 293-LTV cells were not authenticated, however the AAV and LV produced from these cells were titred
by PCR. iBA cells were previously validate by gene expression and functional assay (OCR). HepG2 cells and HEK293Tcells were
validated via PCR.

Mycoplasma contamination

The cells were regularly tested, all cell lines tested were negative for mycoplasma contamination.

Commonly misidentified lines

No commonly misidentified cell lines were used in the study.

(See ICLAC register)
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Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals

C57Bl/6 female mice were used. B6J.129(B6N)-Gt(ROSA)26Sortm1(CAG-cas9*,-EGFP)Fezh/J, Acox1 floxed and Atgl floxed
female mice were used. All the experiments were started when mice were 8 weeks of age.

Wild animals

No wild animals were used in the study.

Field-collected samples

No field collected samples were used in the study.

Ethics oversight

All experiments were approved by the Animal Ethics Committee of Zurich, all animal studies were approved by the Veterinäramt
Zürich.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Human research participants
Policy information about studies involving human research participants
Patients with liver diseases or severe obesity,above 20 years, at both genders, were adults of European (92%) and/or African
(8%) ancestry with different medical treatment

Recruitment

Human liver biopsies were collected in two cohorts and were analyzed for data integration. Liver biopsies of one cohort were
obtained during the work-up of liver disease diagnostics in the outpatient clinic of the Division of Gastroenterology and
Hepatology, University Hospital Basel, Switzerland. The study was carried out in accordance with The Code of Ethics of the
World Medical Association (Declaration of Helsinki) and was approved by the Ethics Committee of North Western Switzerland
(Authorization number EKNZ 2014-362). Written informed consent was obtained from all patients enrolled in this study. Five
to ten millimeters of the liver biopsy cylinder were immediately snap frozen by immersion in liquid nitrogen and stored in
liquid nitrogen vapors until processing and analysis.
Human liver biopsies of the other cohort were obtained from participants of the Biological Atlas of Severe Obesity (ABOS)
cohort (ClinicalTrials.gov identifier NCT01129297), an ongoing prospective cohort study for the longitudinal assessment of
metabolic outcomes after weight loss surgery. The study design has been described previously in details44. Briefly,
participants were adults of European (92%) and/or African (8%) ancestry, who fulfilled the criteria for weight loss surgery,
including severe obesity [body mass index (BMI) ≥40 kg/m2 or ≥ 35 kg/m2 with comorbidities] for at least 5 years and
resistance to medical treatment, and the absence of medical or psychological contraindications to surgery. Patients with
current excessive drinking (daily consumption of alcohol ≥20 g/day for women and ≥ 30 g/day for men), history of past
excessive drinking for a period longer than 2 years at any time in the past 20 years, long-term consumption of hepatotoxic
drugs, or positive screening for chronic liver diseases including positive testing for hepatitis B surface antigen and hepatitis C
virus antibodies, evidence of genetic hemochromatosis, and age < 20 years were excluded. All enrolled patients gave their
informed consent for a comprehensive metabolic phenotyping with tissue, plasma and serum sampling prior to the
intervention.

Ethics oversight

Cohort of Basel group was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of
Helsinki) and was approved by the Ethics Committee of North Western Switzerland (Authorization number EKNZ 2014-362).
Biological Atlas of Severe Obesity (ABOS) cohort was approved with ClinicalTrials.gov identifier NCT01129297 and All
procedures were approved by the C.H.R.U. Lille Ethical committee and were compliant to the French National Ethics
Committee guidelines

Note that full information on the approval of the study protocol must also be provided in the manuscript.
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Policy information about clinical studies
All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.

Clinical trial registration EKNZ 2014-362 and NCT01129297
Study protocol

Protocol of Basel cohort:Liver biopsies of one cohort were obtained during the work-up of liver disease diagnostics in the outpatient
clinic of the Division of Gastroenterology and Hepatology, University Hospital Basel, Switzerland. Five to ten millimeters of the liver
biopsy cylinder were immediately snap frozen by immersion in liquid nitrogen and stored in liquid nitrogen vapors until processing
and analysis. The full protocol is described in previous publication (doi.org/10.1016/j.jhep.2021.04.051)
Protocol of French cohort:participants were adults of European (92%) and/or African (8%) ancestry, who fulfilled the criteria for
weight loss surgery, including severe obesity [body mass index (BMI) ≥40 kg/m2 or ≥ 35 kg/m2 with comorbidities] for at least 5 years
and resistance to medical treatment, and the absence of medical or psychological contraindications to surgery. Patients with current
excessive drinking (daily consumption of alcohol ≥20 g/day for women and ≥ 30 g/day for men), history of past excessive drinking for
a period longer than 2 years at any time in the past 20 years, long-term consumption of hepatotoxic drugs, or positive screening for
chronic liver diseases including positive testing for hepatitis B surface antigen and hepatitis C virus antibodies, evidence of genetic
hemochromatosis, and age < 20 years were excluded. All enrolled patients gave their informed consent for a comprehensive
metabolic phenotyping with tissue, plasma and serum sampling prior to the intervention.
Liver biopsy was systematically planned during the surgical procedure and performed during the first part of the surgical procedure
after trocar insertion and abdominal exploration, within 10 minutes after pneumo-peritoneum installation. A wedge liver surgical
biopsy was performed, fragmented in 30 mg samples, and snap frozen in liquid nitrogen and stored at -80°C. In addition, a needle
biopsy was performed for histological assessment of steatosis. Following staining with H&E saffron, Sirius red, and Perl’s staining,
steatosis was quantified by the percentage of hepatocytes containing fat droplets (amount of steatosis). The full protocol is described
in previous publication (10.1172/JCI68815)

Data collection

First cohort: Liver biopsies of this cohort were obtained during the work-up of liver disease diagnostics in the outpatient clinic of the
Division of Gastroenterology and Hepatology, University Hospital Basel, Switzerland. Five to ten millimeters of the liver biopsy
cylinder were immediately snap frozen by immersion in liquid nitrogen and stored in liquid nitrogen vapors until processing and
analysis to check steatosis level.
Second cohort: Liver biopsies of this cohort were obtained in Lille University Hospital. Liver biopsy was systematically planned during
the surgical procedure and performed during the first part of the surgical procedure after trocar insertion and abdominal exploration,
within 10 minutes after pneumo-peritoneum installation. A wedge liver surgical biopsy was performed, fragmented in 30 mg
samples, and snap frozen in liquid nitrogen and stored at -80°C.A needle biopsy was performed for histological assessment of
steatosis. Following staining with H&E saffron, Sirius red, and Perl’s staining, steatosis was quantified by the percentage of
hepatocytes containing fat droplets (amount of steatosis).
After liver biospy sampling, the samples were further homogenized in ETH, Zurich for protein measurement and data collection

Outcomes

The liver biopsies of different steatosis levels were homogenized to measure ATGL protein level and cysteine sulfenic acid
modification levels and the correlation between steatosis levels and ATGL or ROS levels in the biopsies were analyzed and shown in
the manuscript
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